Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32

Oppenheimer analyst Kostas Biliouris has maintained an 'Outperform' rating on Nurix Therapeutics (NASDAQ: NRIX) and increased the price target from $28 to $32. This adjustment reflects a positive outlook for the company's performance in the market.